News – Jun 01, 2018

Julius Clinical appoints new Chief Commercial Officer

Former PRA executive, Arnoud Huisman, appointed as CCO

Zeist, 1 June 2018 - Julius Clinical’s Board of Directors is pleased to announce that Arnoud Huisman will join the company as its new Chief Commercial Officer. Mr. Huisman succeeds Andrew Copestake, who left the company to pursue other interests earlier this year.


 "I am very pleased to welcome Arnoud to the team of Julius Clinical,” stated Aize Smink, CEO.  “With his proven ability to engage clients, we can continue to build our unique offering of highly specialised scientific and operational services in clinical development for companies who look for a collaborative therapeutically focused partner, to address the challenges with regard to patient access, site engagement and reliable execution of their clinical trials.”

Arnoud Huisman is a highly skilled Senior Executive in the Life Sciences industry with more than 25 years of success spanning pharmaceuticals, biotech, diagnostics and food & nutrition. His broad areas of expertise include innovation, leadership in performance, focus and strategy, P&L, marketing and product development. Throughout his executive career, Arnoud has held several leadership positions, amongst others at Biotrial, NIZO, PRA Health Sciences, and Pharma Industry (Wyeth and Solvay). During his time at PRA, he served as Vice President of Clinic, Senior Vice President of Global Business Development and Senior Vice President of Alliance Management, where he succeeded in winning projects worth approximately $500 million and establishing preferred provider contracts with both Large Pharma as Biotech.

“I am thrilled to join Julius Clinical – the company has an excellent reputation, a great team and the potential to grow into a leadership position as a scientific CRO. It is going to be an exciting journey!” commented Arnoud.

Arnoud holds an MSc in Human Movement Sciences from the Free University, Amsterdam. As a seasoned board member, he has held board positions with ACRON, EUCROF, Dutch Clinical Trial Foundation and Delphi BioScience. He speaks both English and Dutch fluently.